Wie gefährlich ist die medizinische Anwendung von Botulinumtoxin?

 

 Buy Article Permissions and Reprints

Zusammenfassung

Der Erfolg des therapeutischen Einsatzes von Botulinumtoxin seit über 20 Jahren in der Neurologie führte zu einer breiten Akzeptanz dieser giftigsten bekannten biologischen Substanz. Aufgrund der Datenmenge, die wir zur Verfügung haben, gilt die Botulinumtoxintherapie in der Hand des Experten als ein sicheres Therapieverfahren. Zuletzt haben aber wiederholt Berichte in der Boulevardpresse über Todesfälle bei der Anwendung von Botulinumtoxin zu großer Verunsicherung geführt. Auch aus diesem Grund hat das Bundesinstitut für Arzneimittel und Medizinprodukte am 04. September 2008 eine Stellungnahme veröffentlicht. Letztlich sind trotz hunderttausendfacher Anwendung seit der Zulassung in Deutschland 1993 nur 210 Verdachtsfälle schwerer unerwünschter Wirkungen von Botulinumtoxinmedikamenten gemeldet worden, wobei in keinem dieser Fälle ein ursächlicher Zusammenhang mit der Anwendung von Botulinumtoxin sicher erwiesen sei. Zu einem vergleichbaren Ergebnis kam die US Food and Drug Administration wenige Jahre zuvor. Somit gilt nach wie vor, dass bei Einhaltung der empfohlenen Höchstdosen und Würdigung der Begleiterkrankungen multimorbider Patienten systemische Nebenwirkungen extrem selten und bei kosmetischen Indikationen keine Todesfälle beschrieben sind. Möglicherweise steigt die Häufigkeit systemischer Nebenwirkungen durch eine noch genauere Beobachtung unserer Patienten nach Botulinumtoxinbehandlung an.

Summary

The therapeutic application of botulinum toxin in neurology for more than 20 years has lead to a great acceptance of this toxic biological substance. Due to data and experience the treatment with botulinum toxin through an expert is safe. Because of recent articles in the yellow press about death after botulinum toxin treatment patients are uncertain. That was the reason for a statement from the Bundesinstitut für Arzneimittel und Medizinprodukte in 2008. Since 1993 and after thousands of applications only 210 suspicions of severe adverse events were reported, but a casual connection to botulinum toxin could never be shown. The American Food and Drug Administration has the same results. Therefore, rare severe adverse effects can be obtained when dosage is respected and special attention to patients with comorbidity is given. There were no deaths in cosmetics, yet. Because of a closer observation of patients, there could be more adverse events seen.

• Literatur

• 1 Barbano RL. Needle EMG guidance for injection of botulinumtoxin. Needle EMG guidance is useful. MuscleNerve 2001; 24 (11) 1567-1568.
  Google Scholar
• 2 Berweck S. et al. Sonography-guided injection of botulinumtoxin A in children with cerebral palsy. Neuropediatrics 2002; 33 (04) 221-223.
  Article in Thieme ConnectPubMedGoogle Scholar
• 3 Berweck S. et al. Sonography-guided injection of botulinumtoxin in children with cerebral palsy. Lancet 2004; 363 9404 249-250.
  PubMedGoogle Scholar
• 4 Bhatia KP. et al. Generalises muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J Neurol Neurosurg Psychiatry 1999; 67 (01) 90-93.
  CrossrefPubMedGoogle Scholar
• 5 Borodic G. Myasthenic crisis after botulinum toxin. Lanced 1997; 352: 1832.
  Google Scholar
• 6 Ceballos-Baumann A. et al. Blue book dystonia botulinum toxin: Basics – clinical aspects – atlas – evaluation scales. Bonn, Berlin: Child & Brain GmbH; 2007
  Google Scholar
• 7 Ceballos-Baumann A. et al. Dystonie. In: www.dgn.org/leitl.shtml (Ed.). Leitlinien der Deutschen Gesellschaft für Neurologie 2005
  PubMedGoogle Scholar
• 8 Chen R. et al. Effect of muscle activity immediately after botulinum toxin injection for writer’s cramp. Mov Disord 1999; 14 (02) 307-312.
  CrossrefPubMedGoogle Scholar
• 9 Chertow DS. et al. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA 2006; 296 (20) 2476-2479.
  CrossrefPubMedGoogle Scholar
• 10 Comella CL. et al. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology 1992; 42 (04) 878-882.
  CrossrefPubMedGoogle Scholar
• 11 Daelen B. et al. Neurogene Kiefergelenkluxation. Definition und Therapie mit Botulinumtoxin. Nervenarzt 1997; 68 (04) 346-350.
  CrossrefPubMedGoogle Scholar
• 12 De Laet K. et al. Adverse events after botulinum A toxin injections for neurogenic voiding disorders. Spinal Cord 2005; 43 (07) 397-399.
  CrossrefPubMedGoogle Scholar
• 13 Del Polpolo et al. Neurogenic detrusor overactivity treated with English botulinum toxin A: 8-year experience of one single centre. Eur Urol 2008; 53 (05) 1013-1019.
  CrossrefPubMedGoogle Scholar
• 14 Dykstra DD. et al. Treatment of detrusor-sphincter Dyssinergia with botulinum toxin: a double-blind study. Arch Phys Med Rehabil 1990; 71 (01) 24-26.
  PubMedGoogle Scholar
• 15 Emmerson J. Botulinum toxin for spasmodic torticollis in a patient with myasthenia gravis. Mov Disord 1994; 09: 367.
  CrossrefPubMedGoogle Scholar
• 16 Erbguth F. et al. Systemic effect of local botulinum toxin injections unmasks subclinical Lambert Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1993; 56: 1235-1236.
  CrossrefPubMedGoogle Scholar
• 17 Esquenazi A. et al. Electric stimulation to prolong the duration of botulinum toxin type A effect on spasticity: A double-blind, placebo-controlled study, Arch Phys Med Rehabil. 2007 88. 09 E105ABS-Poster 322.
  PubMedGoogle Scholar
• 18 Hasegawa et al. A novel subunit structure of clostridium botulinum serotyp D toxin complex with three extended arms. J Biol Chem 2007; 282 (34) 24777-24783.
  CrossrefPubMedGoogle Scholar
• 19 Haussermann P. et al. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord 2004; 19 (03) 303-308.
  CrossrefPubMedGoogle Scholar
• 20 Herting B. et al. Computed tomographically-controlled injection of botulinum toxin into the longus colli muscle in severe anterocollis. Mov Disord 2004; 19 (05) 588-590.
  CrossrefPubMedGoogle Scholar
• 21 Hesse S. et al. Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett 1995; 201 (01) 37-40.
  CrossrefPubMedGoogle Scholar
• 22 Hesse S. et al. Ankle muscle activity before and after botulinumtoxin therapy for lower limb extensor spasticity in chronic hemiparetic patients. Stroke 1996; 27 (03) 455-460.
  CrossrefPubMedGoogle Scholar
• 23 Hesse S. et al. Botulinum toxin type A and shortterm electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial. Clin Rehabil 1998; 12 (05) 381-388.
  CrossrefPubMedGoogle Scholar
• 24 Kessler KR. et al. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety and antibody frequency. German dystonia study group. J Neurol 1999; 246: 265-274.
  CrossrefPubMedGoogle Scholar
• 25 Kuo HC. et al. Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion. Neurourol Urodyn 2008; 27 (08) 793-796.
  CrossrefPubMedGoogle Scholar
• 26 Kuo HC. et al. Recovery of detrusor function after uretrhral Botulinum A toxin inections in patiens with idiopathic low detrusor contractility and voiding dysfunction. 2007; 69 (01) 57-61.
  PubMedGoogle Scholar
• 27 Kuo HC. et al. Effectiveness of urethral injection of botulinum A toxin in the treatment of voiding dysfunction after radical hysterectomy. Urol Int 2005; 75 (03) 247-251.
  CrossrefPubMedGoogle Scholar
• 28 Meichsner M. et al. Die Wirkung von Botulinum Toxin A auf die vegetative kardiale Innervation. Fortschr Neurol Psychiat 2005; 73: 409-414.
  Article in Thieme ConnectPubMedGoogle Scholar
• 29 Molloy FM. et al. Accuracy of muscle localization without EMG: implications for treatment of limb dystonia. Neurology 2002; 58 (05) 805-807.
  CrossrefPubMedGoogle Scholar
• 30 Reitz A. et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004; 45 (04) 510-515.
  CrossrefPubMedGoogle Scholar
• 31 Schnider P. et al. Erhöhte Restharnmengen nach lokaler Injektion von Botulinum-A-Toxin. Nervenarzt 1995; 66: 465-467.
  PubMedGoogle Scholar
• 32 Schurch B. et al. Botulinum A toxin as a treatment of detrusor-sphincter Dyssynergia in patients with spinal cord injury: MRI controlled transperineal injections. J Neurol Neurosurg Psychiatr 1997; 63: 474-476.
  CrossrefPubMedGoogle Scholar
• 33 Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87 (10) 1044-1049.
  CrossrefPubMedGoogle Scholar
• 34 Stephen DH. et al. Fatal heart block following treatment with botulinum toxin for achalasie. Am J Gastroenterology 2000; 95: 3333.
  CrossrefPubMedGoogle Scholar
• 35 Timothy R. Botulinum toxin type A injections: Adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 2005; 53 (03) 407-415.
  CrossrefPubMedGoogle Scholar
• 36 Westhoff B. et al. Ultrasound-guided botulinum toxin injection technique for the iliopsoas muscle. Dev Med Child Neurol 2003; 45: 829-832.
  Google Scholar
• 37 Wissel et al. EMG for identification of dystonic, tremulous and spastic muscles and techniques for guidance of injections. In: Moore AP, Aumann M. (eds.). Handbook of botulinum toxin treatment. 2nd. ed. London: Blackwell Science; 2003
  Google Scholar
• 38 Wellhöner HH. et al. Allgemeine und systemische Pharmakologie und Toxikologie. 6. Auflage. Heidelberg: Springer; 1997
  Google Scholar
• 39 Yamada S. et al. Effects of aminoglykoside. Ther Toxicol 1986; 24: 130-138.
  Google Scholar